CNSX:CLPharmaceuticals
Cresco Labs (CL): Reassessing Valuation After Historic U.S. Cannabis Rescheduling Boosts Growth Expectations
Cresco Labs (CL) is back in the spotlight after the U.S. government moved to reschedule cannabis from Schedule I to Schedule III, a policy shift management says could materially reshape its tax profile and growth trajectory.
See our latest analysis for Cresco Labs.
The market has started to price in that optimism, with the share price at $1.76 after a 1 month share price return of 55.75 percent and a 1 year total shareholder return of 35.38 percent, even though longer term total shareholder...